alanine + arginine + aspartic acid + 25 other active ingredients: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
alanine + arginine + aspartic acid + 25 other active ingredients: clinical details
Prescribing considerations
- Confirm that oral or enteral nutrition is impossible, insufficient or contraindicated.
- Correct fluid, electrolyte and acid–base disturbances before starting.
- Consider diabetes, impaired lipid metabolism, sepsis, pancreatitis and cardiac, hepatic or renal impairment.
- Account for the product's electrolytes and high sodium content when prescribing additional fluids or electrolytes.
- Provide vitamins and additional trace elements according to individual requirements.
- Use strict aseptic technique and add only substances with documented compatibility.
Contraindications and cautions
- Hypersensitivity to an ingredient or to egg, fish, peanut or soya protein.
- Age under two years.
- Inborn errors of amino-acid metabolism, severe hypertriglyceridaemia, severe coagulopathy, uncontrolled hyperglycaemia or acidosis.
- Severe hepatic failure, intrahepatic cholestasis or severe renal failure without renal replacement therapy.
- Acute thromboembolism, lipid embolism, acute pulmonary oedema or decompensated cardiac failure.
- Life-threatening circulatory instability, inadequate tissue oxygenation or an unstable metabolic state.
Monitoring
- Serum triglycerides and blood glucose.
- Electrolytes, fluid balance and acid–base status.
- Blood-cell counts and coagulation.
- Hepatic and renal function.
- Clinical signs of infection, hypersensitivity, fluid overload and metabolic intolerance.
Clinical pharmacology
This combination supplies amino acids for protein synthesis alongside glucose and medium- and long-chain triglycerides for energy. Soya and fish-oil lipids provide omega-6 and omega-3 fatty acids; electrolytes and zinc contribute to metabolic and fluid balance.
Formulation and product differences
- A three-chamber bag separates glucose, lipid and amino-acid/electrolyte solutions until activation.
- The mixed product is a high-osmolality emulsion intended only for central venous infusion.
- It contains electrolytes and zinc but does not by itself provide every required vitamin or trace element.
- Multiple bag volumes exist, and not all pack sizes may be marketed.
alanine + arginine + aspartic acid + 25 other active ingredients interactions
The clinical team should review all medicines and intravenous products before administration.
Warfarin and other coumarin anticoagulants
Vitamin K1 naturally present in soya-bean oil may alter anticoagulant control, so closer monitoring is required.
Potassium-sparing diuretics, ACE inhibitors and angiotensin-II receptor blockers
These may add to the product's potassium content and increase the risk of hyperkalaemia.
Ciclosporin or tacrolimus
These may increase serum potassium, requiring caution and monitoring.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.